296 related articles for article (PubMed ID: 23026680)
21. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines.
Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Soult JA; Montero I
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2567-70. PubMed ID: 15980249
[TBL] [Abstract][Full Text] [Related]
22. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Muñoz M; Rosso M
Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
[TBL] [Abstract][Full Text] [Related]
23. Role of tachykinin and neurokinin receptors in the regulation of ovine omasal contractions.
Onaga T; Oh-ishi T; Shimoda T; Nishimoto S; Hayashi H
Regul Pept; 2012 Jan; 173(1-3):64-73. PubMed ID: 21971117
[TBL] [Abstract][Full Text] [Related]
24. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
25. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma.
Brener S; González-Moles MA; Tostes D; Esteban F; Gil-Montoya JA; Ruiz-Avila I; Bravo M; Muñoz M
Anticancer Res; 2009 Jun; 29(6):2323-9. PubMed ID: 19528498
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage.
Scholzen TE; Steinhoff M; Sindrilaru A; Schwarz A; Bunnett NW; Luger TA; Armstrong CA; Ansel JC
FASEB J; 2004 Jun; 18(9):1007-9. PubMed ID: 15084523
[TBL] [Abstract][Full Text] [Related]
27. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
28. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
29. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration.
Dong J; Feng F; Xu G; Zhang H; Hong L; Yang J
Gene; 2015 Apr; 560(2):205-10. PubMed ID: 25659767
[TBL] [Abstract][Full Text] [Related]
30. Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway.
Bardelli C; Gunella G; Varsaldi F; Balbo P; Del Boca E; Bernardone IS; Amoruso A; Brunelleschi S
Br J Pharmacol; 2005 Jun; 145(3):385-96. PubMed ID: 15778738
[TBL] [Abstract][Full Text] [Related]
31. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor.
Vigna SR
Neuropeptides; 2001 Feb; 35(1):24-31. PubMed ID: 11346307
[TBL] [Abstract][Full Text] [Related]
32. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
33. Substance P receptor expression in human skin keratinocytes and fibroblasts.
Liu JY; Hu JH; Zhu QG; Li FQ; Sun HJ
Br J Dermatol; 2006 Oct; 155(4):657-62. PubMed ID: 16965412
[TBL] [Abstract][Full Text] [Related]
34. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
[TBL] [Abstract][Full Text] [Related]
35. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
36. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
Bunn PA; Chan D; Stewart J; Gera L; Tolley R; Jewett P; Tagawa M; Alford C; Mochzuki T; Yanaihara N
Cancer Res; 1994 Jul; 54(13):3602-10. PubMed ID: 7516822
[TBL] [Abstract][Full Text] [Related]
37. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
38. The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.
Muñoz MF; Argüelles S; Rosso M; Medina R; Coveñas R; Ayala A; Muñoz M
Biomed Res Int; 2022; 2022():6291504. PubMed ID: 35434136
[TBL] [Abstract][Full Text] [Related]
39. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Michalski CW; Autschbach F; Selvaggi F; Shi X; Di Mola FF; Roggo A; Müller MW; Di Sebastiano P; Büchler MW; Giese T; Friess H
Am J Surg; 2007 Apr; 193(4):476-81. PubMed ID: 17368292
[TBL] [Abstract][Full Text] [Related]
40. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Kast RE
J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
